Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
The objective of this trial is to assess the efficacy and safety of CNM-Au8 as a
remyelinating treatment for vision-impairing MS lesions in participants who have chronic
vision impairment as a result of Relapsing-Remitting Multiple Sclerosis. The primary endpoint
is to assess the efficacy and safety of CNM-Au8 as a remyelinating therapy in patients with
stable RMS. The secondary endpoint is Change in Functional Composite Responder Analysis Score
from Baseline to Week 24.